On Sept. 26, the FDA approved the first truly new antipsychotic in decades: Cobenfy. In clinical trials, it didn’t cause certain side effects that traditionally interfere with medication adherence, including weight gain, lethargy, and movement disorders.
I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically, powerful people rarely invest in new medications for marginalized populations like those with schizophrenia. When it happens, it feels like the system is finally listening to us, acknowledging our quality of life matters.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
